IB-Stim in the News

Clicking the links on this page will take you to third-party websites not sponsored by NeurAxis, Inc. NeurAxis, Inc. makes no claim or warranty of, and is not responsible for the production of any information found in a linked website. Comments regarding IB-Stim or treatment protocols outside of IB-Stim FDA clearance are up to the treating physician’s discretion.

This page contains links that discuss uses of IB-Stim around Functional Abdominal Pain and IBS using percutaneous electrical nerve field stimulator (PENFS) technology, specifically the IB-Stim. Please note, the linked articles may include information and uses of IB-Stim which have not been reviewed or cleared by the U.S. FDA. These links are being provided for informational purposes only. NeurAxis does not recommend or suggest the use of its PENFS IB-Stim device for uses beyond those that are cleared by the U.S. FDA.

  • IB-Stim featured on The Balancing Act, airing on Lifetime Network

    IB-Stim featured on The Balancing Act, airing on Lifetime Network

    April 15, 2024

  • IB-Stim Telepsych Health

    Telepsych Health – Gut Brain Interaction with Dr. Adrian Miranda

    February 21, 2024

  • IB-Stim USA Today

    USA TODAY- Nemours Children’s Health Patient Story

    December 4, 2023

  • IB-Stim Ochsner Health

    Oschner Children’s Article – What is IB-Stim?

    December 16, 2021

  • IB-Stim Avera

    Avera Health Patient Story

    November 29, 2021

  • IB-Stim Fox 2 St. Louis

    Fox 2 St. Louis – SSM Health Medical Minute

    June 16, 2021

A New Standard Of Care

*The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS DEN180057.